期刊文献+

双(3-吗啉丙氧基)姜黄素抗肿瘤活性研究

Antitumor Activity of Bis(3-morpholinopropoxy) Curcumin
下载PDF
导出
摘要 合成双(3-吗啉丙氧基)姜黄素(PR1),研究PR1体内外抗肿瘤活性。姜黄素与N-(3-氯丙基)吗啉反应制备PR1,MTT法评价PR1体外对人肾癌细胞OS-RC-2、786-O和人慢性粒细胞白血病耐药细胞KA的抑制增殖活性,考察PR1体内抑制人结肠癌HT29裸鼠移植性肿瘤活性。PR1体外对肾癌细胞OS-RC-2和786-O抑制活性比姜黄素强,而对白血病耐药细胞KA抑制活性比姜黄素差。PR1体内对BALB/C-nu小鼠HT29皮下移植瘤的抑制作用明显,100 mg/kg·d灌胃的抑制率为55.7%,差别具有显著性(P<0.01),对裸鼠的体重无明显影响。PR1在体内外均有较强抗肿瘤活性。 The objectives of this study were to synthesize bis (3-morpholinopropoxy)eurcumln (PR1) and to evaluate its antitumor activity. PR1 was synthesized from curcumln and N-(3-chlompropyl) morpholine. The in vitro antitumor activities of PR1 was evaluated through MTF assays against gastric carcinoma ceils ( OS-RC-2 and 786-O) and chronic myelogenous leukemia resistance cell (KA). The in vivo antitumor activities of PR1 were evaluated by its growth inhibition of human colon cancer HT29 tumor xenograft in BALB/C-nu nude mice. Compared with curcumln, PR1 showed improved activities against OS-RC-2,786-0 ceUs, while less activities against KA cell. PR1 showed remarkable in vivo tumor growth inhibition activity. A dose of 100 mg/kg . d was able to inhibit the growth of HT29 xenograft in BALB/C-nu nude mice by 55.7%. No obvious decrease on the body weight of tested nude mice was observed. In concluslon,PR1 showed obvious antltumor activities both in vitro and in vivo.
出处 《天然产物研究与开发》 CAS CSCD 北大核心 2015年第4期695-698,共4页 Natural Product Research and Development
基金 福建省科技厅项目(2011J01189) 福建省教育厅项目(JA12138) 国家自然科学基金(81173096)
关键词 姜黄素 姜黄素衍生物 双(3-吗啉丙氧基)姜黄素 抗肿瘤活性 eurcumin curcumin derivatives bis (3-morphoHnopmpoxy) curcumin antitumor activity
  • 相关文献

参考文献1

二级参考文献8

  • 1张艳华,宁华,姜洋.表皮生长因子受体酪氨酸激酶抑制剂吉非替尼[J].中国新药杂志,2004,13(10):947-950. 被引量:13
  • 2Frampton JE, Easthope SE. Gefitinib [J]. Drugs, 2004, 64 (21) : 2475-2492.
  • 3Gibson KH. Preparation of haloanilinoquinazolines as Class I receptor tyrosine kinase inhibitors: WO, 9633980 [P]. 1996-10-31. (CA 1997, 126: 47235)
  • 4Gilday JP, Moody D. Process for the preparation of 4- (3-chloro-4-fluoroanilino) -7-methoxy-6- (3-morpholinopropoxy) quinazoline: WO, 2004024703 [P]. 2004-03-25. (CA 2004, 140: 287403).
  • 5Ramanadham JP, Muddasani PR, Bollepalli NR, et al. An improved process for the preparation of gefitinib: WO, 2005070909 [P]. 2005-08-04. (CA2005, 143: 194029).
  • 6Katrizky AR, Pilarski B, Urogdi L. Efficient conversion of nitriles to amides with basic hydrogen peroxide in dimethyl sulfoxide [J]. Synthesis, 1989, (12): 949-950.
  • 7Adams RR, Whitmore FC. Heterocyclic basic compounds. IV 2-Aminoalkylamino-pyrimidines [J]. JAm Chem Soc, 1945 67(5) : 735-738.
  • 8黄世杰.AstraZeneca公司的gefitinib有希望复合治疗非小细胞肺癌[J].国外医学(药学分册),2003,30(2):118-118. 被引量:4

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部